Anti-CD123 dimeric antigen receptor T cell therapy (Sorrento Therapeutics)

N/A

Report date: 2024/03/29 16:59:16

Base Information

Drug NameAnti-CD123 dimeric antigen receptor T cell therapy (Sorrento Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD123

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A